Новости

The fund with the participation of R-Pharm sold the developer of botulinum toxin to Allergan company

21 Sep, 2018 10:40

The Fund RBV Capital, created with the participation of RVC and R-Pharm, will receive up to 10% of the sale of the Irish Allergan to the American company Bonti. The initial payment will amount to $ 195 million, under certain conditions additional payments may follow.

BIOCAD and SPH Agree to Build a Drug Substance Manufacturing Facility in China

13 Sep, 2018 13:22

BIOCAD and SPH Agree to Build a Drug Substance Manufacturing Facility in China

SAINT PETERSBURG, Russia--(BUSINESS WIRE)--This year at the Eastern Economic Forum in Vladivostok, BioCad and Shanghai Pharmaceutical Holding entered into a Memorandum of Understanding to create two joint ventures for production, clinical development, registration, and marketing of several high-cost medicines based on monoclonal antibodies in the People's Republic of China.

RPEF announced the closing of a deal with the pharmaceutical company R-Pharm

12 Sep, 2018 11:16

Russian Private Equity Fund announced the closing of a deal with the pharmaceutical company R-Pharm Alexey Repyk. The share of the company bought by the joint Russian-Japanese equity fund is estimated at 10%, the deal value is not disclosed.

Active Component has attracted a minority financial investor to the company

05 Sep, 2018 16:14

Active Component has attracted a minority financial investor to the company

Elbrus Capital II, a private equity fund, has announced investment in Active Component.

The Presidium of the Presidential Council for Strategic Development has approved the national «Healthcare» project with a budget of 1.3 trillion rubles

04 Sep, 2018 11:45

The Presidium of the Presidential Council for Strategic Development has approved the national «Healthcare» project with a budget of 1.3 trillion rubles

The President’s Council of the Russian Federation on strategic development and national projects has approved the national project "Healthcare". For its execution, more than 1.3 trillion rubles will be invested within six years,-said Veronika Skvortsova, Minister of Health, at the meeting of the Presidium of the Council...

Gilead localizes the production of medicines for HIV and hepatitis C on Pharmstandard facilities

04 Sep, 2018 11:18

Gilead Sciences has concluded an agreement on the production of Sovaldi (sophosbuvir) for the treatment of chronic hepatitis C and Truvada (tenofovir + emmitcytabin) for the treatment of the HIV on Pharmstandard facilities. The issue of inclusion of drugs in EDL list will be considered by the specialized commission of the Ministry of Health on September 4...

The Cabinet of Ministers rejected the idea to allow the sale of pharmaceuticals in grocery stores

27 Jun, 2018 11:53

The Cabinet of Ministers rejected the idea to allow the sale of pharmaceuticals in grocery stores

In Russia nonprescription drugs will not be sold in trade networks, Kommersant reports. The bill draft, ratifying cease of the monopoly of pharmacies for these drugs, was criticized by representatives of the pharmaceutical industry and the Ministry of Health.

Pharmaceutical distributors have stored up stocks for months ahead

25 Jun, 2018 11:29

High expectations of pharmaceutical manufacturers on the dynamics of sales in the Russian retail market led to the excess of some distributors’ trade stocks in early 2018. This situation is being solved in different ways: someone tries to convince manufacturers to adjust the sales plan, someone interchanges bonuses and volume.

The Council of Federation has adopted a law about simplified registration of pharmaceuticals

01 Jun, 2018 10:12

Senators have approved amendments to the law "On medicine circulation", allowing companies to register generics under one international non-proprietary name, but under different brand names. It expands the possibilities of contract manufacturing for domestic pharmaceutical manufacturers...

 

Biocad has signed an agreement with The Almazov National Medical Research Centre on the development of cancer immunotherapy

29 May, 2018 10:49

Biocad Biotechnology Company has signed an agreement with The Almazov National Medical Research Centre on conducting joint research in the field of treatment of cancer with the help of chimeric antigenic receptors (CAR-T). The head of  Biocad Dmitry Morozov promised that the cost of creating an individual cellular immune drug for one patient will amount to 16 million rubles – half as cheap as imported analogues...

https://vademec.ru/news/2018/05/25/biokad-podpisala-soglashenie-o-sovmestnykh-issledovaniyakh-s-tsentrom-almazova/